Paradigm Biopharmaceuticals targets 2019-20 milestones for OA-MPS-BMEL pipeline
Pharmaxis anti-fibrotic pipeline review highlights drug with strong pre-clinical data for bone marrow cancer myelofibrosis
Kazia Therapeutics to share pipeline results with market and clinicians
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.